LAVAL, QC, April 4, 2019 /CNW/ - BELLUS Health Inc.
(TSX: BLU) ("BELLUS Health" or the "Company"), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of chronic cough and other hypersensitization-related
disorders, today announced that Roberto
Bellini, President and Chief Executive Officer of BELLUS
Health, will present a corporate overview of the Company, including
an update on its lead program BLU-5937 for the treatment of chronic
cough, at two upcoming healthcare investor conferences.
Conference Presentation Details:
Event: Needham & Company 18th Annual Healthcare
Conference
Date/Time: Wednesday, April 10, 2019 at 3:30 p.m. ET
Location: New York,
NY
Event: Bloom Burton & Co. Healthcare Investor
Conference
Date/Time: Wednesday, May 1, 2019 at 9:30 a.m. ET
Location: Toronto, ON
Live webcasts from the Needham and Bloom Burton conference
presentations may be accessed on the Events and Presentations page
under the Investors & News section of the Company's website.
Following the events, archived webcasts and presentations will be
available on the BELLUS Health website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of chronic cough
and other hypersensitization-related disorders. The Company's lead
drug candidate, BLU-5937, is being developed for the treatment of
chronic cough.
Chronic cough is a cough lasting more than eight weeks and is
associated with significant adverse physical, social and
psychosocial effects on health and quality of life. It is estimated
that approximately 26 million adults in the United States suffer from chronic cough
with more than 2.6 million having unexplained or refractory chronic
cough lasting for more than a year. There are limited treatment
options for refractory chronic cough including no currently
approved therapeutics.
SOURCE BELLUS Health Inc.